Study of and Investigational drug in Participants with

Recruiting

18 years - 99 years

All

Phase N/A

50 participants needed

1 Location

Brief description of study

The research study is being conducted to evaluate the safety and effectiveness of MK-6482 when compared to treatment with everolimus for renal cell carcinoma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Renal Cell Carcinoma,Cancer
Age: 18 years - 99 years
Gender: All

Male or Female Age 18 or older Has locally advanced or metastatic clear cell renal cell carcinoma (RCC)

Updated on 04 Aug 2024. Study ID: 842957

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Study of and Investigational drug in Participants with Advanced Renal Cell Carcinoma That Has Progressed

Brief description of study

Eligibility of study

Find a site

Interested in the study